The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) on Thursday approved Journavx (suzetrigine), a new non-opioid painkiller that promises to be nonaddictive. Journavx is approved to ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...